Accelr8 Says Fiscal Q2 Revenues Rise 53 Percent as Loss Cut by More Than Half | GenomeWeb
NEW YORK (GenomeWeb News) – Accelr8 today said fiscal second-quarter revenues rose 53 percent as R&D spending decreased 57 percent and losses narrowed 42 percent.
 
Total receipts for the three months ended Jan. 31 increased to $85,000 from 55,000 year over year.
 
More than half the revenues came from license fees, with smaller amounts coming from option fees and from OptiChem sales.
  
R&D spending fell to $250,000 from $570,000 year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.